Buch, Englisch, 240 Seiten, Format (B × H): 176 mm x 232 mm, Gewicht: 481 g
Buch, Englisch, 240 Seiten, Format (B × H): 176 mm x 232 mm, Gewicht: 481 g
Reihe: Pharmaceutical Science Series
ISBN: 978-0-415-26365-8
Verlag: CRC Press
Recent advances in cytotoxins and immunotoxins are accelerating our understanding of cancer and leading to more effective therapeutic treatments. Although a large number of articles have been published on these cytotoxins and immunotoxins, this important information has yet to be compiled into one comprehensive resource.
For the first time, Cytotoxins and Immunotoxins for Cancer Therapy: Clinical Applications presents state-of-the-art information on various cytotoxins and immunotoxins in a single, highly anticipated publication. The editors bring together leading researchers to summarize their work and discuss clinical trial data concerning some of the most widely studied tumors. The book describes Pseudomonas exotoxin (PE)-based immunotoxins and presents the latest results from clinical trials for the treatment of recurrent glioblastoma and other human cancers. It reviews the role of ricin-based immunotoxins for the treatment of lymphoma, explores several DT-based immunotoxins, and details the preclinical and clinical development of the first FDA-approved cytotoxin.
With a focus on clinical developmental approaches to the use of cytotoxins and immunotoxins, this book discusses exciting possibilities for cancer therapy. It is a valuable resource for scientists, researchers, and clinicians involved in the development of new treatments that can help keep cancer under control, and may ultimately lead to a cure.
Zielgruppe
Professional and Professional Reference
Autoren/Hrsg.
Weitere Infos & Material
Preface: An Overview of Immunotoxins and Cytotoxins in Clinical Trials. PART 1. PSEUDOMONAS EXOTOXIN (PE)-BASED IMMUNOTOXINS/CYTOTOXINS. Targeting of Pseudomonas Exotoxin-based Immunotoxins to Hematologic Malignancies. Interleukin-4-targeted Cytotoxin for Recurrent Glioblastoma Therapy. Interleukin-13 Receptors and Development of IL-13-Pseudomonas Exotoxin for Human Cancer Therapy. PART 2. RICIN-BASED IMMUNOTOXINS/CYTOTOXINS. Ricin Immunotoxins in Lymphomas. PART 3. DIPHTHERIA TOXIN (DT)-BASED IMMUNOTOXINS/CYTOTOXINS. Diphtheria-based Immunotoxins: Targeting Overexpressed Interleukin-13 Receptor and Urokinase-type Plasminogen Activator Receptor on Glioblastoma Multiforme. DAB389IL-2 (Ontak): Development and Therapeutic Applications. Transferrin Diphtheria Toxin for Brain Tumor Therapy. GM-CSF Receptor Targeted Therapy of Human Leukemia. VEGF-diphtheria toxin for Targeting of Tumor Blood Vessels. PART 4. MISCELLANEOUS. cBR-96-doxorubicin (SGN-15) for Metastatic Breast Cancer Therapy. Anti-CD33 Calicheamicin Immunoconjugate Therapy of Acute Myeloid Leukemia.
